Copyright
        ©2008 The WJG Press and Baishideng.
    
    
        World J Gastroenterol. Oct 21, 2008; 14(39): 6065-6071
Published online Oct 21, 2008. doi: 10.3748/wjg.14.6065
Published online Oct 21, 2008. doi: 10.3748/wjg.14.6065
            Table 1 Details of prescriptions of the two clarithromycin products
        
    | Clarithromycin | ||
| Sustained-release | Immediate release | |
| Total number of prescriptions | 949 | 197 | 
| Number of prescriptions for alimentary disease | 164 | 110 | 
| Mean age (range) yr | 45.9 (18-82) | |
| Male:Female | 137:137 | |
| Number of prescriptions for anti-H pylori therapy | 159 | 96 | 
| Triple therapy | 151 | 83 | 
| PPI/Clarithromycin/Amoxicillin | 43 | 58 | 
| PPI/Clarithromycin/Furazolidone | 44 | 21 | 
| PPI/Clarithromycin/Levofloxacin | 63 | 1 | 
| PPI/Clarithromycin/Metronidazole | 1 | 1 | 
| PPI/Clarithromycin/Tinidazole | 0 | 2 | 
| Quadruple therapy | 5 | 6 | 
| PPI/Bismuth/Amoxicillin/Clarithromycin | 0 | 2 | 
| PPI/Bismuth/ Furazolidone/Clarithromycin | 1 | 3 | 
| PPI/Bismuth/Levofloxacin/Clarithromycin | 4 | 1 | 
| Dual therapy | 3 | 7 | 
| Clarithromycin/PPI | 2 | 7 | 
| Clarithromycin/Ranitidine bismuth citrate | 1 | 0 | 
            Table 2 Diagnoses of patients on clarithromycin-based therapy
        
    | Diagnoses | Clarithromycin | |
| SR | IR | |
| Chronic gastritis | 90 | 87 | 
| Peptic ulcer | 40 | 5 | 
| Duodenal ulcer | 9 | 5 | 
| Gastro-oesophageal reflux disease | 5 | 1 | 
| Chronic gastritis, H pylori infection | 4 | 3 | 
| Gastric ulcer | 1 | 4 | 
| Chronic gastritis, Gastric ulcer | 2 | 1 | 
| Gastro-oesophageal reflux disease, Gastric ulcer | 1 | |
| H pylori infection | 2 | |
| Chronic gastritis, Peptic ulcer | 1 | 3 | 
| Peptic ulcer, H pylori infection | 1 | |
| Mesenteric lymphadenitis | 7 | |
| Abdominal pain of unknown origin | 2 | |
            Table 3 Concomitant drugs used in clarithromycin-based triple therapy
        
    | Comedicated drugs | Clarithromycin | |
| SR | IR | |
| PPI | ||
| Omeprazole | 17 | 6 | 
| Lansoprazole | 68 | 6 | 
| Pantoprazole | 30 | 66 | 
| Esomeprazole magnesium | 15 | 11 | 
| Rebeprazole | 23 | 21 | 
| Antibiotics | ||
| Amoxicillin | 38 | 63 | 
| Furazolidone | 47 | 24 | 
| Levofloxacin | 67 | 2 | 
| Metronidazole | 1 | 1 | 
| Tinidazole | 0 | 13 | 
| Amoxicillin/clavulanate potassium | 5 | 0 | 
            Table 4 CYP3A based clinical significant drug interactions with clarithromycin
        
    | Concurrent medications primarily metabolized by CYP3A | Clarithromycin | References | |
| SR | IR | ||
| Alprazolam and zolpidem | 1 | [6,7] | |
| Midazolam | 1 | [6,8] | |
| Amlodipine | 1 | 2 | [9] | 
| Levoamlodipine | 1 | ||
| Nifedipine | 1 | [10] | |
| Carbamazepine | 1 | [11] | |
| Nifedipine, clopidogrel and atorvastatin | 1 | [10,12-14] | |
| Amlodipine and ergoloid mesylate sustained release capsules | 1 | [9,15] | |
| Prednisone | 1 | [16] | |
- Citation: Zhou Q, Zhu LL, Yan XF, Pan WS, Zeng S. Drug utilization of clarithromycin for gastrointestinal disease treatment. World J Gastroenterol 2008; 14(39): 6065-6071
- URL: https://www.wjgnet.com/1007-9327/full/v14/i39/6065.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.6065

 
         
                         
                 
                 
                 
                 
         
                         
                         
                        